| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GINS2 |
| Uniprot No | Q9Y248 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-185aa |
| 氨基酸序列 | MASMTGGQQMGRGEFGSMDAAEVEFLAEKELVTIIPNFSLDKIYLIGGDL GPFNPGLPVEVPLWLAINLKQRQKCRLLPPEWMDVEKLEKMRDHERKEET FTPMPSPYYMELTKLLLNHASDNIPKADEIRTLVKDMWDTRIAKLRVSAD SFVRQQEAHAKLDNLTLMEINTSGTFLTQALNHMYKLRTNLQPLESTQSQ DF |
| 预测分子量 | 23 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于GINS2重组蛋白的参考文献示例(注：文献为假设性示例，实际文献需通过学术数据库检索确认)：
---
1. **标题**: *GINS2 Promotes Ovarian Cancer Progression Through Regulation of DNA Replication and Cell Cycle*
**作者**: Li X, Zhang Y, Chen H
**摘要**: 本研究通过构建GINS2重组蛋白，揭示了其在卵巢癌细胞中调控DNA复制起始的作用，并发现GINS2过表达通过激活CDK2通路加速细胞周期进程，促进肿瘤生长。
2. **标题**: *Expression and Purification of Recombinant Human GINS2 Protein in E. coli*
**作者**: Wang R, Liu T, Zhou M
**摘要**: 文章描述了利用大肠杆菌表达系统高效表达并纯化重组GINS2蛋白的优化方法，通过His标签亲和层析获得高纯度蛋白，为后续功能研究提供可靠工具。
3. **标题**: *Structural Insights into GINS2 Interaction with DNA Polymerase ε in the Replisome*
**作者**: Tanaka S, Nakagawa T
**摘要**: 通过X射线晶体学分析重组GINS2蛋白与DNA聚合酶ε的复合体结构，阐明GINS2在复制叉中稳定聚合酶活性的分子机制，强调了其在基因组稳定性中的关键作用。
4. **标题**: *GINS2 as a Prognostic Biomarker in Hepatocellular Carcinoma: Role in Tumor Metastasis*
**作者**: Kim J, Park S, Lee JH
**摘要**: 利用重组GINS2蛋白进行体外功能实验，发现其通过EMT(上皮间质转化)通路促进肝癌细胞迁移和侵袭，提示GINS2可作为潜在治疗靶点。
---
**建议**：实际文献可通过PubMed、Web of Science等平台，以关键词“GINS2 recombinant”、“GINS2 AND DNA replication”或结合疾病名称(如“cancer”)检索。关注近年发表于《Nucleic Acids Research》《Oncogene》等期刊的研究。
**Background of GINS2 Recombinant Protein**
The GINS complex, a critical component of eukaryotic DNA replication machinery, consists of four subunits (SLD5. PSF1. PSF2. and PSF3) that are evolutionarily conserved. Among these, GINS2 (also known as PSF2) plays an essential role in the initiation and elongation phases of DNA replication by stabilizing the CMG (CDC45-MCM-GINS) helicase complex, which unwinds DNA during replication. GINS2 ensures proper assembly and progression of the replication fork, maintaining genomic stability and cell cycle fidelity.
Recombinant GINS2 protein is produced using heterologous expression systems (e.g., *E. coli* or mammalian cells*) to study its structure, interactions, and functional mechanisms in vitro. Its production often involves tagging (e.g., His-tag) for purification and detection. Researchers utilize GINS2 recombinant protein to investigate replication-related diseases, such as cancers linked to replication stress or mutations in GINS subunits. For example, dysregulated GINS2 expression has been associated with tumor progression, making it a potential diagnostic marker or therapeutic target.
Additionally, GINS2 recombinant protein serves as a tool for screening inhibitors that disrupt replication in rapidly dividing cells, offering avenues for anticancer drug development. Its study also contributes to understanding developmental disorders caused by replication defects. Overall, GINS2 recombinant protein is a vital resource for unraveling DNA replication mechanisms and their implications in health and disease.
×
